News
3 Stocks at 52-Week Highs Still Worth Buying
Stocks near or at their 52-week highs are rarely compelling buys. These highfliers, after all, generally tend to take a breather upon reaching new heights or, worse still, reverse course. With this
3 Stocks at 52-Week Highs Still Worth Buying
Stocks near or at their 52-week highs are rarely compelling buys. These highfliers, after all, generally tend to take a breather upon reaching new heights or, worse still, reverse course. With this
3 Stocks at 52-Week Highs Still Worth Buying
Stocks near or at their 52-week highs are rarely compelling buys. These highfliers, after all, generally tend to take a breather upon reaching new heights or, worse still, reverse course. With this
3 Stocks at 52-Week Highs Still Worth Buying
Stocks near or at their 52-week highs are rarely compelling buys. These highfliers, after all, generally tend to take a breather upon reaching new heights or, worse still, reverse course. With this
Lockheed Martin Corporation Q2 Earnings: Shares Rise, Outlook Boosted
The Lockheed Martin Q2:F17 earnings report was released before opening bell this morning. The defense contractor posted earnings of $3.23 per share on $12.7 billion in revenue, compared to the....
AveXis Inc.: Buy at the High?
In the time it takes most newborns to sprout their first teeth, AveXis Inc. (NASDAQ: AVXS) looks ready to sink its teeth into the biotech industry. Since its market debut in early 2016, stellar
OENEO : Information relative au nombre de titres et de droits de vote au 30 juin 2017
Oeneo SA
21 Boulevard Haussmann – 75009 Paris
SA à Conseil d'Administration
Au capital de 62 904 186 euros
RCS Paris 322 828 260
Paris le 18 juillet 2017
DECLARATION MENSUELLE RELATIVEAU....
This Rewards Card Is a Huge Success for JPMorgan Chase
Even though JPMorgan Chase's (NYSE: JPM) shares have dropped since the bank reported earnings at the end of last week, investors shouldn't interpret this as a sign that something was wrong with the
This Rewards Card Is a Huge Success for JPMorgan Chase
Even though JPMorgan Chase's (NYSE: JPM) shares have dropped since the bank reported earnings at the end of last week, investors shouldn't interpret this as a sign that something was wrong with the
5 Big Pharma Stocks With the Best Drug Pipelines
Big pharma companies can't rest on their laurels. Continual research and development is critical to ensure long-term success. Some of that R&D pays off more than others, though.Market research firm
5 Big Pharma Stocks With the Best Drug Pipelines
Big pharma companies can't rest on their laurels. Continual research and development is critical to ensure long-term success. Some of that R&D pays off more than others, though.Market research firm
JetBlue Airways Details the Next Phase of Mint Expansion
A little more than three years ago, JetBlue Airways (NASDAQ: JBLU) introduced its upscale Mint service on select flights between New York and Los Angeles. Mint flights use a dedicated fleet of Airbus
5 Ways Gilead Sciences Could Spend Its Cash Hoard
Gilead Sciences (NASDAQ: GILD) has a growth problem.Long known for its enormous HIV franchise and market share, Gilead branched out into hepatitis C (HCV) in 2012. While that market provided plenty of
5 Ways Gilead Sciences Could Spend Its Cash Hoard
Gilead Sciences (NASDAQ: GILD) has a growth problem.Long known for its enormous HIV franchise and market share, Gilead branched out into hepatitis C (HCV) in 2012. While that market provided plenty of
5 Ways Gilead Sciences Could Spend Its Cash Hoard
Gilead Sciences (NASDAQ: GILD) has a growth problem.Long known for its enormous HIV franchise and market share, Gilead branched out into hepatitis C (HCV) in 2012. While that market provided plenty of
These 2 Companies Have No Competition
Warren Buffett has long championed the idea of investing in companies with durable competitive advantages. He believes that a business with true "moat" can more easily defend its market share from
Forget GW Pharmaceuticals: These 2 Stocks Are Better Buys
Yes, GW Pharmaceuticals (NASDAQ: GWPH) is the biggest marijuana-focused biotech stock on the market. The company's promising cannabinoid Epidiolex could very well become a blockbuster success story in
Forget GW Pharmaceuticals: These 2 Stocks Are Better Buys
Yes, GW Pharmaceuticals (NASDAQ: GWPH) is the biggest marijuana-focused biotech stock on the market. The company's promising cannabinoid Epidiolex could very well become a blockbuster success story in
Forget GW Pharmaceuticals: These 2 Stocks Are Better Buys
Yes, GW Pharmaceuticals (NASDAQ: GWPH) is the biggest marijuana-focused biotech stock on the market. The company's promising cannabinoid Epidiolex could very well become a blockbuster success story in
Have Investors Been Overlooking Dollar General?
Dollar General (NYSE: DG) has a business model that seems to confuse many investors.The company has expanded rapidly by meeting a specific need in the communities it serves for nearby stores that sell
Have Investors Been Overlooking Dollar General?
Dollar General (NYSE: DG) has a business model that seems to confuse many investors.The company has expanded rapidly by meeting a specific need in the communities it serves for nearby stores that sell
3 Ways to Earn a Promotion
For many a worker, a promotion can be the key toward a better life. In most cases getting bumped up to a new job means more money, more perks, and, of course, more responsibility.Earning that step up
3 Stocks With Dominating Business Advantages
If you are a long-term, buy-and-hold investor, there's nothing more important to analyze than the sustainable business advantage -- or "moat" -- of the company you are investing in.Of course, there's
3 Stocks With Dominating Business Advantages
If you are a long-term, buy-and-hold investor, there's nothing more important to analyze than the sustainable business advantage -- or "moat" -- of the company you are investing in.Of course, there's
3 Stocks With Dominating Business Advantages
If you are a long-term, buy-and-hold investor, there's nothing more important to analyze than the sustainable business advantage -- or "moat" -- of the company you are investing in.Of course, there's